Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug:241:27-34.
doi: 10.1016/j.forsciint.2014.04.020. Epub 2014 Apr 24.

Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine

Affiliations

Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine

Allan J Barnes et al. Forensic Sci Int. 2014 Aug.

Abstract

Introduction: The recent emergence and widespread availability of many new synthetic cannabinoids support the need for an accurate and high-throughput urine screen for these new designer drugs. We evaluated performance of the immunalysis homogeneous enzyme immunoassay (HEIA) to sensitively, selectively, and rapidly identify urinary synthetic cannabinoids.

Methods: 2443 authentic urine samples were analyzed with the HEIA that targets JWH-018 N-pentanoic acid, and a validated LC-MS/MS method for 29 synthetic cannabinoids and metabolites. Semi-quantitative HEIA results were obtained, permitting performance evaluation at and around three cutoffs (5, 10 and 20 μg/L), and diagnostic sensitivity, specificity and efficiency determination. Performance challenges at ±25 and ±50% of each cutoff level, cross-reactivity and interferences also were evaluated.

Results: Sensitivity, specificity, and efficiency of the immunalysis HEIA K2 Spice kit with the manufacturer's recommended 10 μg/L cutoff were 75.6%, 99.6% and 96.8%, respectively, as compared to the reference LC-MS/MS method with limits of detection of 0.1-10 μg/L. Performance at 5 μg/L was 92.2%, 98.1% and 97.4%, and for the 20 μg/L cutoff were 62.9%, 99.7% and 95.4%. Semi-quantitative results for in-house prepared standards were obtained from 2.5-30 μg/L, and documented acceptable linearity from 5-25 μg/L, with inter-day imprecision <30% (n = 17). Thirteen of 74 synthetic cannabinoids evaluated were classified as highly cross-reactive (≥50% at 10 μg/L); 4 showed moderate cross-reactivity (10-50% at 10 μg/L), 30 low cross-reactivity (<10% at 500 μg/L), and 27 <1% cross-reactivity at 500 μg/L. There was no interference from 102 investigated compounds. Only a mixture containing 1000 μg/L each of buprenorphine/norbuprenorphine produced a positive result above our proposed cutoff (5 μg/L) but below the manufacturer's recommended cutoff concentration (10 μg/L).

Conclusion: The Immunalysis HEIA K2 Spice kit required no sample preparation, had a high-throughput, and acceptable sensitivity, specificity and efficiency, offering a viable method for screening synthetic cannabinoids in urine that cross-react with JWH-018 N-pentanoic acid antibodies.

Keywords: HEIA; Immunoassay; Synthetic cannabinoids.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
General structures of synthetic cannabinoids (A–M).
Fig. 2
Fig. 2
Linearity evaluation with the quantile-quantile plot for fortified performance challenge samples (5-30 μg/L) analyzed in 17 batches. Duplicate values were averaged in each run and mean concentrations were plotted vs. known concentrations. Straight line corresponds to 100% agreement with the predicted concentration. Dashed lines are ±30% of target concentrations.

Similar articles

Cited by

References

    1. Bosker WM, Huestis MA. Oral fluid testing for drugs of abuse. Clin Chem. 2009;55:1910–1931. - PMC - PubMed
    1. United Nations Office on Drugs Crime. World Drug Report 2012. United Nations Office on Drugs and Crime; Vienna: 2012.
    1. Ameri A. The effects of cannabinoids on the brain. Progr Neurobiol. 1999;58:315–348. - PubMed
    1. Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011;11:36–51. - PMC - PubMed
    1. Malan TP, Jr, Ibrahim MM, Deng H, Mata HP, Vanderah T, Porreca F, et al. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol. 2003;3:62–67. - PubMed

Publication types